Hemolytic-uremic syndrome future or investigational therapies

Several disease-modifying treatments have been proposed for STEC-associated HUS, but effective targeted therapy remains unproven. Because Shiga toxin 2 has been identified in serum and in or on circulating blood cells and microvesicles shortly before or during HUS, extraintestinal Shiga toxin remains a potential therapeutic target. Until effective therapies are validated, management should focus on rapid diagnosis, close monitoring, avoidance of harmful interventions, prevention of volume depletion, and correction of modifiable risk factors.^[1]

• ASA and dipyridamole not effective alone,benefit when added to plasma exchange
• In poorly responsive or resistant disease, INCREASE PLASMA EXCHANGE
• Then consider:

• prednisone (1 mg/kg per day)
• methylprednisolone (125 mg IV bid)
• Vincristine
• IVIG

Template:WH Template:WS